^
    9d
    Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer. (PubMed, Eur J Med Res)
    KCNK1 was significantly overexpressed in BC. A complex and sophisticated three-dimensional spatial transcriptional regulatory network existed in the KCNK1 TSS and promoted the upregulated of KCNK1 expression. The high expression of KCNK1 might be involved in the cell cycle, cellular metabolism, and tumour microenvironment through the regulation of potassium channels, and ultimately contributed to the deterioration of BC.
    Journal • IO biomarker
    |
    FOXA1 (Forkhead Box A1)
    |
    paclitaxel • docetaxel • vinblastine
    10d
    Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, RenJi Hospital
    New P1/2 trial • Metastases
    |
    cisplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
    14d
    IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. (PubMed, Theranostics)
    IL4R-Abx accumulated at tumors, heightened immune-stimulatory cells while reducing immune-suppressing cells, and hampered tumor growth and metastasis in mice more efficiently than Abx and Ctrl-Abx. These results indicate that IL4R-targeting allows enhancement of M2-macrophage shaping into M1-like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • IL4 (Interleukin 4) • IL4R (Interleukin 4 Receptor)
    |
    albumin-bound paclitaxel
    15d
    ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P1, N=28, Recruiting, ProDa BioTech, LLC | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Sep 2023
    Enrollment open • Trial initiation date • Combination therapy • Metastases
    |
    PKM (Pyruvate Kinase M1/2)
    |
    gemcitabine • albumin-bound paclitaxel
    16d
    Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Jan 2024
    Enrollment closed • Trial primary completion date • Combination therapy
    |
    gemcitabine • albumin-bound paclitaxel
    21d
    Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition. (PubMed, Eur J Med Chem)
    Zebrafish acute toxicity experiments showed that high concentrations of 4r did not cause death or malformation of zebrafish embryos. All these results demonstrated that 4r would be a promising lead candidate for further development of novel PI3K and tubulin dual inhibitors in cervical cancer treatment.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    22d
    Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=32, Active, not recruiting, Translational Drug Development | Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    albumin-bound paclitaxel
    23d
    HNSCC: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=46, Recruiting, Fulgent Pharma LLC. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Erbitux (cetuximab) • paclitaxel • nanoencapsulated paclitaxel (FID-007)
    25d
    Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia. (PubMed, Curr Med Sci)
    Overall, these findings suggest that HZX-02-059 is a promising agent for the treatment of B-ALL patients resistant to conventional therapies.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    HZX-02-059
    25d
    A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment. (PubMed, J Exp Clin Cancer Res)
    The clinical response to ONCOFID-P-B™ in bladder CIS likely relies on several components of the TME, and the combined evaluation of intra-tumoral macrophages density and CD44v6 expression is a potentially new predictive biomarker for patient response. Overall, our data allow to advance a potential rationale for combinatorial treatments targeting the immune infiltrate such as immune checkpoint inhibitors, to make bladder CIS more responsive to ONCOFID-P-B™ treatment.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ICAM1 (Intercellular adhesion molecule 1)
    |
    CD44 expression
    |
    paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)
    29d
    PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients (clinicaltrials.gov)
    P2, N=81, Recruiting, Fudan University
    New P2 trial • Surgery • Metastases
    |
    gemcitabine • albumin-bound paclitaxel
    1m
    QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, NantPharma, LLC | Phase classification: P1b/2 --> P1/2 | N=64 --> 0 | Trial completion date: Dec 2024 --> Dec 2023 | Suspended --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2023
    Phase classification • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Cynviloq (paclitaxel polymeric micelle formulation)
    1m
    Utilising UPLC-QTOF-MS/MS to determine the phytochemical profile and in vitro cytotoxic potential of Ziziphora capitata L. with molecular docking simulation. (PubMed, Nat Prod Res)
    The molecular docking simulation was performed inside the effective sites of VEGFR-2 and TS as anticancer targets for the top ten phytochemicals. The results showed higher binding energy values for VEGFR-2 than for TS compared to vinblastine and co-crystallized ligands.
    Preclinical • Journal
    |
    KDR (Kinase insert domain receptor)
    |
    vinblastine
    1m
    Exploring the potential of Ziziphus nummularia and luteolin-7-O-glucoside as tubulin inhibitors in cancer therapy and survival. (PubMed, Sci Rep)
    Luteolin-7-O-glucoside is the lead candidate for further research and development as an anti-cancer agent. In addition, this study suggests that herbal treatment could switch on mechanisms of adaptation and survival in cancer cells.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase)
    1m
    FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, University of Southern California
    New P1 trial • Surgery
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • LAG3 (Lymphocyte Activating 3) • CD38 (CD38 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCR7 (Chemokine (C-C motif) receptor 7) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • PRDM1 (PR/SET Domain 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
    |
    paclitaxel • nanoencapsulated paclitaxel (FID-007)
    1m
    Case Report: Macula Structural and Functional Assessment in Nab-Paclitaxel-Related Cystoid Macular Edema. (PubMed, Ophthalmic Surg Lasers Imaging Retina)
    The introduction of topical dorzolamide 1% in one eye demonstrated further rapid resolution of edema. We demonstrate the objective and subjective visual changes and recovery of nab-paclitaxel-related cystoid macular edema. [Ophthalmic Surg Lasers Imaging Retina 2024;55:xx-xx.].
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • PTEN mutation + HR positive
    |
    albumin-bound paclitaxel
    2ms
    Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma (clinicaltrials.gov)
    P3, N=58, Recruiting, The Third Affiliated hospital of Zhejiang Chinese Medical University
    New P3 trial
    |
    albumin-bound paclitaxel
    2ms
    GIST Oral Paclitaxel(Liporaxel) (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Asan Medical Center
    New P2 trial
    |
    paclitaxel • imatinib • sunitinib • Stivarga (regorafenib) • Liporaxel (paclitaxel oral)
    2ms
    PTCA199-9: Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • albumin-bound paclitaxel
    2ms
    Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Surgery
    |
    gemcitabine • albumin-bound paclitaxel • metformin
    2ms
    Single Dual-specific Anti-PD-L1/TGF-β Antibody Synergizes with Chemotherapy as Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma: a Preclinical Experimental Study. (PubMed, Int J Surg)
    Our results suggest that the BiTP combinatorial chemotherapy is a promising neoadjuvant therapy for PDAC.
    Preclinical • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    gemcitabine • albumin-bound paclitaxel
    2ms
    A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    gemcitabine • albumin-bound paclitaxel
    2ms
    Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=12, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Oct 2028 | Trial primary completion date: Mar 2024 --> Oct 2028
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    2ms
    Establishment of a patient-specific avatar organoid model derived from endoscopic ultrasonography-guided fine needle biopsy for timely clinical application in pancreatic ductal adenocarcinoma. (PubMed, Gastrointest Endosc)
    This PDAC PDO platform allows several therapeutic drugs to be tested within a short time window and opens the possibility for timely personalized medicine as a "Patient Avatar Model" in clinical practice.
    Journal • Biopsy
    |
    ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    albumin-bound paclitaxel
    2ms
    Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov)
    P1/2, N=24, Recruiting, University of Maryland, Baltimore | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    gemcitabine • albumin-bound paclitaxel
    2ms
    Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors. (PubMed, Future Med Chem)
    Docking studies displayed good binding into HDAC1 and six pockets and tubulin polymerization protein. Compound 4b could be considered a good antitumor candidate to go further into in vivo and clinical studies.
    Journal
    |
    HDAC1 (Histone Deacetylase 1)
    2ms
    Study SC-101 in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Tianjin ConjuStar Biologics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer (clinicaltrials.gov)
    P1/2, N=237, Recruiting, Regeneron Pharmaceuticals | N=83 --> 237 | Trial completion date: Dec 2026 --> Feb 2030 | Trial primary completion date: Dec 2026 --> Feb 2030
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MET overexpression
    |
    Libtayo (cemiplimab-rwlc) • REGN5093-M114
    2ms
    Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors (clinicaltrials.gov)
    P=N/A, N=1000, Completed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown status --> Completed | Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Sep 2021 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date • Real-world evidence • Real-world
    |
    albumin-bound paclitaxel
    2ms
    The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=100, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    PALB2 mutation
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    2ms
    SWOG 1815: Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers (clinicaltrials.gov)
    P3, N=452, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Jan 2024 --> May 2024
    Trial completion date • Metastases
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    3ms
    Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. (PubMed, Biomedicines)
    Analysis of one patient still alive from the first group, diagnosed with mTNBC in 2019, showed a complete metabolic response (CMR) after a composite approach implicating first-line mCHT followed by second-line epirubicin and third-line nab-paclitaxel, and was chosen for subsequent molecular characterization. Additionally, we found changes in the expression of oncogenes, such as MYC and AKT, along with their respective proteins. Overall, our data suggest that a first-line treatment with mCHT followed by MTD might be effective by negatively regulating stemness traits usually associated with the emergence of drug resistance.
    Journal • Metastases
    |
    NOTCH1 (Notch 1)
    |
    MYC expression • NOTCH1 expression
    |
    albumin-bound paclitaxel • epirubicin
    3ms
    Suppression of hypoxia-induced CAV1 autophagic degradation enhances nanoalbumin-paclitaxel transcytosis and improves therapeutic activity in pancreatic cancer. (PubMed, Eur J Pharmacol)
    Furthermore, both in vivo and in vitro studies confirmed that suppressing the autophagic degradation of CAV1 via EC-specific ATG5 knockdown or hydroxychloroquine sulfate (HCQ) treatment significantly enhanced nab-paclitaxel translocation across the endothelial barrier into pancreatic cancer cells and amplified the inhibitory effect of nab-paclitaxel on pancreatic tumour growth. The stimulation of CAV1 expression by EC-specific overexpression of exogenous CAV1 or administration of gemcitabine hydrochloride (GE) had the same effect. These results demonstrated that suppressing CAV1 autophagic degradation is a novel translatable strategy for enhancing nab-paclitaxel chemotherapeutic activity in the treatment of pancreatic cancer.
    Journal
    |
    CAV1 (Caveolin 1) • ATG5 (Autophagy Related 5)
    |
    CAV1 expression
    |
    gemcitabine • albumin-bound paclitaxel • hydroxychloroquine
    3ms
    A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=319, Recruiting, Mersana Therapeutics | N=166 --> 319 | Trial completion date: Jan 2026 --> May 2027 | Trial primary completion date: Jan 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    emiltatug ledadotin (XMT-1660)
    3ms
    Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. (PubMed, Drug Resist Updat)
    FGFR1 drives chemoresistance and tumor aggressiveness, which FGFRi can reverse.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    FGFR1 expression
    |
    gemcitabine • albumin-bound paclitaxel
    3ms
    Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC (clinicaltrials.gov)
    P2, N=128, Recruiting, First Affiliated Hospital Bengbu Medical College | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • AiTan (rivoceranib) • albumin-bound paclitaxel
    3ms
    Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    albumin-bound paclitaxel
    3ms
    Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (clinicaltrials.gov)
    P2 | N=67 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2023 ➔ Dec 2024
    Trial completion date
    |
    MammaPrint • BluePrint
    |
    carboplatin • albumin-bound paclitaxel
    3ms
    Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    albumin-bound paclitaxel
    3ms
    OPERA: Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=72, Completed, Daehwa Pharmaceutical Co., Ltd. | Unknown status --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Liporaxel (paclitaxel oral)
    3ms
    Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, CHA University | Trial primary completion date: Nov 2023 --> Sep 2024
    Trial primary completion date • Metastases
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    3ms
    Biomarker Discovery in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, CHA University | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Metastases
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel